Tarsus Pharmaceuticals
TARS
TARS
74 hedge funds and large institutions have $252M invested in Tarsus Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 20 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
1.94% less ownership
Funds ownership: 76.98% → 75.04% (-1.9%)
15% less capital invested
Capital invested by funds: $298M → $252M (-$45.9M)
80% less call options, than puts
Call options by funds: $6K | Put options by funds: $30K
Holders
74
Holding in Top 10
2
Calls
$6K
Puts
$30K
Top Buyers
| 1 | +$1.46M | |
| 2 | +$1.23M | |
| 3 | +$451K | |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$409K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$393K |
Top Sellers
| 1 | -$3.96M | |
| 2 | -$2.97M | |
| 3 | -$2.11M | |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$795K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$465K |